| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
As a bile acid metabolite, 7-keto-Deoxycholic acid does not have a specific defined biological target in the same way as a drug. However, bile acids and their metabolites interact with various receptors and signaling pathways including the farnesoid X receptor (FXR), the G protein-coupled bile acid receptor (TGR5/GPBAR1), and other nuclear receptors. 7-keto-Deoxycholic acid may modulate these pathways, influencing bile acid synthesis, glucose metabolism, lipid metabolism, and energy homeostasis. The compound is also a substrate or product of microbial enzymes involved in bile acid metabolism, including 7α-hydroxysteroid dehydrogenases and 7β-hydroxysteroid dehydrogenases. By studying this metabolite, researchers can gain insights into the complex interplay between the gut microbiome, bile acid metabolism, and host physiology. The compound is a valuable tool for studying bile acid biology and the role of the gut microbiome in health and disease.
|
|---|---|
| ln Vitro |
7-ketolithocholic acid exhibits an increased rate of biotransformation when equimolar amounts of non-metabolized deoxycholic acid are added [1]. Deoxycholic acid induces 7-ketolithocholic acid, which is subsequently metabolized [1]. 3.7% of 2 mM cholic acid is converted to 7-ketodeoxycholic acid and 81.7% to deoxycholic acid by the E. lentum-like c-25 in an anaerobic culture [2]. Under anaerobic culture, E. lentum-like c-25 converts 1.1% of 150 mg/mL of cholic acid into 7-ketodeoxycholic acid and 91.5% of the original acid into deoxycholic acid [2].
In vitro, 7-keto-Deoxycholic acid has been studied for its role in bile acid metabolism. When equimolar amounts of non-metabolized deoxycholic acid are added, 7-ketolithocholic acid exhibits an increased rate of biotransformation. Deoxycholic acid induces 7-ketolithocholic acid, which is subsequently metabolized. In anaerobic culture, E. lentum-like c-25 converts 3.7% of 2 mM cholic acid to 7-ketodeoxycholic acid and 81.7% to deoxycholic acid. Under similar conditions, 1.1% of 150 mg/mL of cholic acid is converted to 7-ketodeoxycholic acid and 91.5% to deoxycholic acid. These in vitro studies demonstrate the microbial conversion of cholic acid to 7-keto-Deoxycholic acid and other bile acid metabolites. The compound's role as a metabolite makes it useful for studying bile acid transformation pathways and the enzymes involved in these processes. |
| ln Vivo |
In vivo, 7-keto-Deoxycholic acid is a metabolite of cholic acid produced by gut microbiota including Clostridium absonum. The compound can be detected in biological samples such as feces, bile, and plasma, reflecting the activity of the gut microbiome in bile acid metabolism. The compound may play a role in regulating bile acid homeostasis and influencing host metabolism through interactions with bile acid receptors. However, specific in vivo effects of exogenously administered 7-keto-Deoxycholic acid have not been extensively reported. The compound is primarily studied as a metabolite marker and as a tool for understanding bile acid metabolism and gut microbiome function. Researchers interested in in vivo applications should consult the primary literature for updated information.
|
| Enzyme Assay |
In vitro enzyme assays for 7-keto-Deoxycholic acid focus on its role as a substrate or product of microbial enzymes involved in bile acid metabolism. 7α-hydroxysteroid dehydrogenases and 7β-hydroxysteroid dehydrogenases catalyze the interconversion of 7-hydroxy and 7-keto bile acids. These enzyme activities can be measured using spectrophotometric assays that monitor NAD(P)H production or consumption, or by HPLC analysis of substrate and product. The compound's conversion from cholic acid by gut bacteria (e.g., Clostridium absonum, E. lentum-like c-25) can be studied in anaerobic cultures. These assays are useful for characterizing the enzymes and bacteria involved in bile acid metabolism and for studying the factors that influence bile acid transformation.
|
| Cell Assay |
Cell-based assays for 7-keto-Deoxycholic acid are not extensively documented. As a bile acid metabolite, the compound may be studied in cell lines relevant to bile acid biology, such as hepatocytes (e.g., HepG2), intestinal epithelial cells (e.g., Caco-2), or cells expressing bile acid receptors (e.g., FXR, TGR5). Cells would be treated with the compound at various concentrations, and effects on gene expression (e.g., FXR target genes), signaling pathways, and cellular functions would be assessed. However, specific cell-based assay protocols for 7-keto-Deoxycholic acid are not well-documented in the available literature. Researchers should develop appropriate cell-based assays based on the compound's mechanism of action and research objectives.
|
| Animal Protocol |
In vivo animal experiments with 7-keto-Deoxycholic acid are not extensively documented. As a bile acid metabolite, the compound could be administered to animal models to study its effects on bile acid metabolism, gut microbiome function, and host physiology. Typical study designs would involve administration of the compound (oral, intraperitoneal, or intravenous) to rodents, followed by collection of biological samples (blood, bile, feces, tissues) for analysis of bile acid profiles, metabolic parameters, and gene expression. However, no specific in vivo protocols have been reported in the available literature. Researchers should consult primary literature and conduct appropriate studies based on their research questions.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-keto-Deoxycholic acid have not been extensively characterized. As a bile acid metabolite, it is expected to be absorbed in the intestine and undergo enterohepatic circulation, similar to other bile acids. The compound has molecular weight 406.56 and molecular formula C24H38O5. It is a white to off-white solid powder with melting point 54-60°C and logP 3.656. The compound is soluble in organic solvents. Storage: powder at -20°C for 3 years, in solvent at -80°C for 1 year. Specific pharmacokinetic parameters such as half-life, Cmax, AUC, and bioavailability have not been reported. Researchers planning in vivo studies should conduct appropriate pharmacokinetic characterization.
|
| Toxicity/Toxicokinetics |
Toxicology data for 7-keto-Deoxycholic acid are limited in publicly available sources. As a naturally occurring bile acid metabolite, the compound is expected to have relatively low toxicity, but specific toxicology studies have not been reported. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. The compound should be stored properly and disposed of in accordance with applicable regulations. Researchers should consult the material safety data sheet (MSDS) for detailed safety information. No specific toxicity data (LD50, organ-specific toxicity, etc.) have been reported.
|
| References | |
| Additional Infomation |
3α,12α-Dihydroxy-7-oxo-5β-cholic acid is a 7-oxosteroid and oxo-5β-cholic acid. It is the conjugate acid of 3α,12α-dihydroxy-7-oxo-5β-cholic acid.
7-keto-Deoxycholic acid has CAS number 911-40-0, molecular formula C24H38O5, and molecular weight 406.56. It is also known as 7-ketolithocholic acid, 3α,12α-dihydroxy-7-oxo-5β-cholic acid, and 7-keto-3α,12α-dihydroxycholanic acid. The compound is a metabolite of cholic acid produced by Clostridium absonum and can also be converted from Lactobacillus and Bifidobacterium under specific conditions. It is a 7-oxosteroid and oxo-5β-cholic acid, and it is the conjugate acid of 3α,12α-dihydroxy-7-oxo-5β-cholic acid. The compound is useful for studying bile acid metabolism and gut microbiome function. Purity: ≥98%. Storage: powder at -20°C for 3 years, in solvent at -80°C for 1 year. Not approved for clinical use; for research purposes only. The compound is a valuable tool for studying the role of bile acids and their metabolites in health and disease. |
| Molecular Formula |
C24H38O5
|
|---|---|
| Molecular Weight |
406.55552
|
| Exact Mass |
406.272
|
| CAS # |
911-40-0
|
| PubChem CID |
188292
|
| Appearance |
White to off-white solid powder
|
| Density |
1.18g/cm3
|
| Boiling Point |
583ºC at 760mmHg
|
| Melting Point |
54-60ºC
|
| Flash Point |
320.4ºC
|
| Index of Refraction |
1.55
|
| LogP |
3.656
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2C(=O)C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
|
| InChi Key |
RHCPKKNRWFXMAT-RRWYKFPJSA-N
|
| InChi Code |
InChI=1S/C24H38O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-18,20,22,25,27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,20+,22+,23+,24-/m1/s1
|
| Chemical Name |
(4R)-4-[(3R,5S,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-7-oxo-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~245.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4597 mL | 12.2983 mL | 24.5966 mL | |
| 5 mM | 0.4919 mL | 2.4597 mL | 4.9193 mL | |
| 10 mM | 0.2460 mL | 1.2298 mL | 2.4597 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA